[18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab

[18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab

Immune checkpoint inhibitors have changed the paradigm of cancer treatment; however, non-invasive biomarkers of response are still needed to identify candidates for non-responders. We aimed to investigate whether immunotherapy [18F]FDG PET radiomics signature (iRADIOMICS) predicts response of metast...

Full description

Bibliographic Details
Main Authors: Valentinuzzi Damijan, Vrankar Martina, Boc Nina, Ahac Valentina, Zupancic Ziga, Unk Mojca, Skalic Katja, Zagar Ivana, Studen Andrej, Simoncic Urban, Eickhoff Jens, Jeraj Robert
Format: Article
Language:English
Published: Sciendo 2020-07-01
Series:Radiology and Oncology
Subjects:
anti-pd-1
[18f]fdg pet/ct
non-small-cell lung cancer
radiomics analysis
iradiomics
Online Access:https://doi.org/10.2478/raon-2020-0042

Internet

https://doi.org/10.2478/raon-2020-0042

Similar Items